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ABSTRACT 
Objective: To develop an accurate, precise and linear Reverse Phase High Performance Liquid Chromatographic (RP-HPLC) method and validate as 
per ICH guidelines for the quantitative estimation of Solifenacin succinate (5mg) in tablets.  
Methods: The optimized method uses a reverse phase column, Enable Make C18G (250 X 4.6 mm; 5μ), a mobile phase of triethylammonium 
phosphate buffer (pH 3.5): acetonitrile in the proportion of 30:70 v/v, flow rate of 1.0 ml/min and a detection wavelength of 210 nm using a UV 
detector.  
Results: The developed method resulted in Solifenacin succinate eluting at 3.5 min. Solifenacin succinate exhibited linearity in the range 10-
30μg/ml. The precision is exemplified by relative standard deviation of 0.76%. Percentage Mean recovery was found to be in the range of 98-102, 
during accuracy studies. The limit of detection (LOD) and limit of quantitiation (LOQ) was found to be 7.65μg/ml and 23.19μg/ml respectively.  
Conclusion: A rapid, accurate, precise and linear RP-HPLC method was developed and validated for the quantitative estimation of solifenacin 
succinate in SOLITEN (5mg) tablets as per ICH guidelines and hence it can be used for routine analysis in various pharmaceutical industries.  
Keywords: RP-HPLC, Solifenacin succinate, Method development, Validation. 
 
Solifenacin succinate (Figure 1) is a competitive muscarinic 
acetylcholine receptor antagonist. Muscarinic receptor antagonists 
are widely used for treatment of the syndrome of overactive bladder 
and urge urinary incontinence [1-4]. The binding of acetylcholine to 
these receptors, particularly the M3 receptor subtype, plays a critical 
role in the contraction of smooth muscle.  
INTRODUCTION 
By preventing the binding of acetylcholine to these receptors, 
Solifenacin reduces smooth muscle tone in the bladder, allowing the 
bladder to retain larger volumes of urine and reducing the number 
of incontinence episodes. IUPAC name of Solifenacin succinateis 
Butanedioic acid, compound with (1S)-(3R)-1-azabicyclo [2.2.2] oct-
3-yl 3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate (1:1), 
having an empirical formula of C23H26N2O2. C4H6O4
 
 and a 
molecular weight of 480.55. It is freely soluble at room temperature 
in water, Glacial acetic acid, dimethyl sulfoxide and methanol [1-4]. 
 
Fig. 1: Structure of Solifenacin succinate 
 
Literature survey reveals chromatographic methods for the 
analysis of Solifenacin succinatein various pharmaceutical dosage 
forms [1-7]. Very little literature is cited on spectrophotometric 
methods [8-9]. We here report a totally new, simple, accurate and 
precise RP-HPLC method for determination of assay of Solifenacin 
succinate in SOLITEN tablets and validate the developed method 
as per ICH guidelines. 
MATERIALS AND METHODS 
Chemicals and Reagents 
Analytically pure sample of Solifenacin succinate with purities 
greater than 99% was obtained as a gift sample from Rachem 
Pharma, Hyderabad, India and tablet formulation [SOLITEN] was 
procured from MEDPLUS Pharmacy, Hyderabad, India with labelled 
amount 5mg of SOLIFENACIN SUCCINATE. Acetonitrile (HPLC 
grade), water (HPLC grade), Triethylamine (AR Grade) and ortho 
phosphoric acid (AR Grade) were obtained from SD Fine chemicals 
(Hyderabad, India), 0.45μm Nylon membrane filters were obtained 
from Spincotech Private Limited, Hyderabad, India.  
Instrument 
HPLC analysis was performed on Shimadzu Prominence Liquid 
Chromatography comprising a LC-20AD pump, Shimadzu SPD-20A 
Prominence UV-VISIBLE detector and a reverse phase C18 column, 
Enable Make C18G (250 X 4.6 mm; 5μ). Manually operating 
Rheodyne injector with 20 μL sample loop was equipped with the 
HPLC system. The HPLC system was controlled with “Labsolutions 
lite” software. An electronic analytical weighing balance (0.1mg 
sensitivity, Shimadzu AY 220), digital pH meter (DELUX model 101), 
a sonicator (sonica, model 2200 MH) and UV-Visible 
Spectrophotometer (Shimadzu UV-1800 series, software-UV probe 
version 2.42) were used in this study.  
Method 
Selection of Wavelength 
Suitable wavelength for the HPLC analysis was determined by 
recording UV spectrum in the range of 200-400 nm for solifenacin 
succinate. Suitable wavelength selected was 210 nm (Figure 2). 
Chromatographic conditions 
The developed method uses a reverse phase C18 column, Enable 
Make C18G (250 X4.6 mm; 5μ), mobile phase consisting of 
triethylammonium phosphate buffer (adjusted using 30% v/v of 
ortho phosphoric acid pH 3.5): acetonitrile in the proportion of 
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30:70 v/v. The mobile phase was set at a flow rate of 1.0 ml/min and 
the volume injected was 20μl for every injection. The detection 
wavelength was set at 210 nm.  
Buffer Preparation 
The buffer solution was prepared by adding 5 ml of triethylamine to 
1000 ml of HPLC grade water and later pH was adjusted to 3.5 using 
30% v/v of ortho phosphoric acid in water. The buffer was then 
filtered through 0.45 μm nylon membrane filter. 
 
 
Fig. 2: UV spectrum of solifenacin succinate 
 
Mobile phase Preparation 
The mobile phase was prepared by mixing acetonitrile and buffer in 
the ratio of 70:30 v/v and later it was sonicated for 10 minutes for 
the removal of air bubbles.  
Preparation of stock and working standard solution 
10mg of solifenacin succinate was accurately weighed and taken in 
100 ml clean and dry volumetric flask containing 50 ml of diluent 
(same as mobile phase) and then sonicated for 2 minutes to dissolve. 
Later the solution was made up to the mark using the mobile phase. 
This is considered as the stock standard solution (100µg/ml). From 
the stock solution, 2 ml was pipetted out and to 10 ml using the 
mobile phase to get a concentration of 20µg/ml, treated as 100% 
target concentration.  
Preparation of stock and working sample solution 
Ten tablets were weighed separately and the average weight was 
determined. The average weight was weighed from the ten tablets 
grinded in a pestle and mortar, transferred to a 100 ml volumetric 
flask containing 100 ml diluent and then stirred for 10 minutes, 
followed by filtration through 0.45µ nylon membrane filter to get 
sample stock solution of 50µg/ml. 4 ml of the above stock solution 
was pipetted out and made up to 10 ml to get working sample 
solution equivalent to a concentration of working standard of 
20µg/ml. 
RESULTS AND DISCUSSION 
Method Development 
A Reverse phase HPLC method was developed keeping in mind the 
system suitability parameters i. e. Tailing factor (T), number of 
theoretical plates (N), runtime and the cost effectiveness. The 
optimized method developed resulted in the elution of solifenacin 
succinate at 3.5 min. Figures 3 and 4 represent chromatograms of 
blank solution and the standard solution (20µg/ml) respectively. 
The total run time is 5 minutes. System suitability tests are an 
integral part of method development and are used to ensure 
adequate performance of the chromatographic system. Retention 
time (Rt), number of theoretical plates (N) and peak asymmetric 
factor was evaluated for six replicate injections of the standard at 
the working concentration. The results are given in Table 1. 
 
 
Fig. 3: Typical Chromatogram of Blank solution 
 
 
Fig. 4: Typical chromatogram of the standard solution 
 
Table 1: System suitabilitystudies results 
Parameters* Solifenacin Succinate 
Retention time (min) 3.5 
Number Of Theoretical plates (N) 4427 
Tailing factor (T) 1.8 
* Mean of six injections 
 
In order to test the applicability of the developed method to a 
commercial formulation, SOLITEN was chromatographed at working 
concentration (20µg/ml) and it is shown in Figure 5. The sample peak 
was identified by comparing the retention time with the standard drug 
Figure 4. System suitability parameters were within the acceptance 
limits, ideal for the chromatographed sample. Integration of separated 
peak area was done and drug concentration was determined by using 
the peak area concentration relationship obtained in the 
standardization step. The protocol affords reproducible assay of the 
drug in the sample ranging between 98 and 102%, which is the 
standard level in any pharmaceutical quality control. 
 
 
Fig. 5: Typical chromatogram for the tablet formulation. 
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Validation of the analytical method is the process that establishes by 
laboratory studies in which the performance characteristics of the 
method meet the requirements for the intended analytical 
application. RP-HPLC method developed was validated according to 
International Conference on Harmonization (ICH) guidelines [10] for 
validation of analytical procedures.  
The method was validated for the parameters like system suitability, 
specificity, linearity, accuracy, precision, limit of detection (LOD) and 
limit of quantitiation (LOQ). 
Specificity 
Figures 3-5 for blank, standard drug solution and sample 
chromatogram reveal that the peaks obtained in the standard 
solution and sample solution at working concentrations are only 
because of the drugs as blank have no peak at the retention time of 
Solifenacin succinate. Accordingly it can be concluded that, the 
method developed is said to be specific. 
Precision 
System precision 
Six replicate injections of the standard solution at the working 
concentration showed % RSD (Relative Standard Deviation) less 
than 2 concerning peak area for the drug, which indicates the 
acceptable reproducibility and thereby the precision of the system. 
System precision results are tabulated in Table 2. 
Method precision 
Method precision was determined by performing the assay of the 
sample under the tests of repeatability (Intraday precision) at 
working concentration.  
  
Table 2: System precision results 
Injection number   Solifenacin succinate 
 (n) Rt Peak Area 
1 3.4 1492445 
2 3.4 1461491 
3 3.5 1500096 
4 3.7 1468792 
Average 1480706 
SD 18483.6 
% RSD 1.2 
 
Repeatability (Intraday precision) 
Six consecutive injections of the sample from the same 
homogeneous mixture at working concentration showed % RSD less 
than 2 concerning % assay for the drug which indicate that the 
method developed is method precise by the test of repeatability and 
hence can be understood that the method gives consistently 
reproducible results (Table 3). 
 
Table 3: Intra day precision results 







S. D. 0.772 
% R. S. D. 0.76 
 
Linearity 
Standard solutions of Solifenacin succinate at different 
concentrations level (50%, 75%, 100%, 125%, 150% and 175%) 
were prepared. Calibration curve was constructed by plotting the 
concentration level of drug versus the corresponding peak area. The 
results show an excellent correlation between peak area and 
concentration level of drug within the concentration range (50-
150µg/ml) for the drug and the results are given in Tables 4-5. The 
correlation coefficient of Solifenacin succinate is greater than 0.995, 
which meet the method validation acceptance criteria and hence the 
method is said to be linear. 
Equation 
Regression  
Coefficient 0.998 0.998 0.997 0.998 
Accuracy 
Accuracy was determined by means of recovery experiments, by the 
determination of % mean recovery of sample at three different 
levels (50-150%). At each level, three determinations were 
performed. Percent mean recovery was calculated as shown in Table 
6. The accepted limits of recovery are 98% - 102% and all observed 
data are within the required range which indicates good recovery 
values and hence the accuracy of the method developed. 
Sensitivity 
Sensitivity of measurement of Solifenacin succinate by use of the 
proposed method was estimated in terms of the limit of quantitation 
(LOQ) and the limit of detection (LOD). The limit of detection (LOD) 
and limit of quantitiation (LOQ) was found to be 7.65μg/ml and 
23.19μg/ml respectively. 
 
Table 4: Linearity of the chromatography system 
Drug Linearity range (µg/ml) R Slope 2 Intercept 
Solifenacin succinate 10-30 0.993 62640.66 -63443.8 
  
Table 5: Calibration data for Solifenacin succinate 
% Level 
 






Average peak areas 
50 10 630289 709347 644157 661264.3 
75 15 905511 942002 986204 944572.33 
100 20 1270490 1259200 1242898 1257529.33 
125 25 1537008 1521841 1529393 1529414 
150 30 1993979 1905241 1905366 1934862 
Regression y=7.70x+36 y=7.70x+34.2 y=7.70x+36.8 y=7.7x+35.65 
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Table 6: Results of Accuracy studies for Solifenacin succinate 
Concentration level (%) *%Mean recovery  
 50 100.31  
100 101.3  
150 101.6  
*Mean of three replicates 
 
CONCLUSION 
A reverse phase HPLC isocratic method developed has been 
validated as per ICH guidelines in terms of specificity, accuracy, 
precision, linearity, limit of detection and limit of quantitation, for 
the quantitative estimation of Solifenacin succinate in tablets. The 
precision is exemplified by relative standard deviation of 0.76%. A 
good linear relationship was observed for the drug between 
concentration ranges of 10 and 30µg/ml. Accuracy studies revealed 
that mean recoveries were between 98 and 102%, indicative of 
accurate method. Accordingly it can be concluded that the developed 
reverse phase isocratic HPLC method is accurate, precise and linear 
and therefore the method can be used for the routine analysis of 
Solifenacin succinate in tablets. 
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